IMI announces conference call and webcast to discuss worldwide licensing agreement with McNeil Consumer Healthcare to market cardiovascular disease test TORONTO, June 1 /PRNewswire-FirstCall/ -- Late on Friday, May 28, 2004, IMI International Medical Innovations Inc. (Amex: IME; TSX:IMI), a world leader in predictive medicine, together with its wholly-owned Swiss subsidiary, concluded an exclusive worldwide non-Canadian licensing agreement with McNeil Consumer Healthcare, a Johnson & Johnson company (NYSE:JNJ), for IMI's non-invasive cardiovascular risk assessment technology. McNeil and its worldwide affiliates will market and distribute IMI's predictive tests for coronary artery disease under the brand name PREVU(x) Coronary Heart Disease Predictor. Under the financial terms of the agreement, IMI will sell products to McNeil and receive an ongoing royalty on McNeil's sales of those products. IMI will also receive a $3.0-million up-front payment as well as a series of milestone payments of up to approximately $15.75 million. This amount is in addition to $3.3 million in milestone payments from IMI's existing Canadian license agreement. ------------------------------------------------------------------------- Conference Call and Webcast IMI will hold a conference call and webcast today, June 1, 2004, at 10 a.m. ET. To access the conference call, please dial (416) 640-4127 in Toronto, or 1-800-814-4860 elsewhere in North America. A live audio webcast will be available at http://www.imimedical.com/ or http://www.newswire.ca/ and subsequently archived on both sites. To access the replay via telephone, which will be available until June 8, 2004, please dial (416) 640-1917 or 1-877-289-8525 and enter the passcode 21051734. B-Roll Coordinates Television stations can downlink a b-roll on June 1, 2004 from 10 a.m. (ET) to 10:15 a.m. (ET). Satellite coordinates are: AMC 9, Transponder 4 Audio subcarrier 6.2 and 6.8 Downlink frequency 3780 horizontal ------------------------------------------------------------------------- About IMI IMI is a world leader in predictive medicine, dedicated to developing rapid, non-invasive tests for the early detection of life-threatening diseases, particularly cardiovascular disease and cancer. The company's head office is located in Toronto, and its research and product development facility is at McMaster University in Hamilton, Ontario. For further information, please visit the company's website at http://www.imimedical.com/. This release contains forward-looking statements that reflect the company's current expectations regarding future events. The forward- looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company's quarterly, annual and other regular filings. DATASOURCE: IMI International Medical Innovations Inc. CONTACT: Brent Norton, President and CEO; Sarah Borg-Olivier, Director, Communications; Ron Hosking, Vice President, Finance and CFO; (416) 222-3449,

Copyright